Opening a new era for XRP: DRML miner releases innovative smart cloud mining contract, enjoy XRP rewards every day
Boost Mining Potential Maximize your mining potential — DRML Miner now supports direct XRP mining with daily XRP payouts, in addition to AI-optimized contracts for BTC, ETH, DOGE, USDC, and more for stable, diversified returns.
As Ripple's XRP ecosystem flourishes around the world, DRML Miner is proud to announce a major development in the cryptocurrency mining space: the official launch of XRP-centric cloud mining contracts. These flexible short-term contracts are now available on web and mobile platforms, allowing users to mine XRP remotely and receive daily XRP rewards – no mining hardware, no complex setup, and no experience required. For the first time, retail participants can participate in the XRP economy through a streamlined, fully integrated platform.
Browse the DRML Miner website or download the app now.
XRP Cloud Mining is here – simple, smart, and rewarding
Traditionally seen as a token for cross-border payments and institutional use, XRP has now entered a new phase with DRML Miner's latest innovation – user-friendly cloud mining. Participants can mine XRP directly or rely on DRML Miner's smart AI engine to switch between high-yield cryptocurrencies such as BTC, ETH, DOGE, USDC, etc. to optimize their earnings. All earnings are paid daily in your preferred cryptocurrency, ensuring stable returns regardless of market fluctuations.
Designed for everyday users and professional investors, the solution enables users to earn a stable crypto income anytime, anywhere.
Key Features of DRML Miner Cloud Mining Contracts
– Full XRP Integration: Users can now deposit, buy, mine, and withdraw XRP directly within the platform.
– Multi-Currency Mining Support: Mine and settle earnings in BTC, ETH, DOGE, USDC, USDT, SOL, LTC, and BCH.
– AI Revenue Optimization: Proprietary algorithms dynamically allocate mining power to the highest performing assets to maximize mining revenue.
– 100% Remote Access: No hardware required – fully accessible via the DRML Miner mobile app or browser.
– Capital Protection: All contracts include a full return of principal at the end of the term, reducing risk and increasing assets.
Mining Contracts to Fit Every Budget and Strategy
DRML Miner offers a variety of cloud mining contracts with XRP-based deposits and withdrawals. Each contract is designed for flexibility, risk control, and predictable returns:
$10 Contract – 1 Day – Earn $0.6 per Day
$100 Contract – 2 Days – Earn $3.50 per Day
$500 Contract – 5 Days – Earn $6.50 per Day
$5,000 Contract – 30 Days – Earn $77.50 per Day
$50,000 Contract – 50 Days – Earn $975 per Day
Whether testing the waters or scaling a long-term strategy, DRML Miner offers a low-risk, high-transparency option to achieve a steady daily income in XRP.
Click here to explore more contract options.
Why does DRML Miner's XRP mining stand out?
– Available to everyone: No mining equipment, no setup, no complexity — just click to earn money.
– XRP native integration: Deposit, mine, and withdraw XRP in one unified ecosystem.
– Stable returns, smart allocation: The AI engine dynamically adjusts mining strategies in real time, maximizing returns and ensuring stable daily earnings on supported cryptocurrencies.
– Multi-asset flexibility: Choose to mine XRP or invest in top currencies — with just one contract
– Instant setup, global access: Works on any mobile device or browser — fully encrypted and secure
Get started today in 3 easy steps:
Sign up – create an account and get a $10 welcome bonus
Choose a plan – activate a short-term or long-term contract (1-60 days available)
Start earning – monitor daily profits and withdraw in your favorite coins
Start mining XRP today at https://drmlminers.com/ or the DRML Miner mobile app (available for iOS and Android).
XRP Mining, Towards a Digital Future
Since 2018, a spokesperson for DRML Miner said: 'We believe that participation in cryptocurrency activities should not come at the expense of the environment. By leveraging renewable energy and AI optimization, we are committed to providing users with efficient and sustainable mining services.
Despite the volatility of the cryptocurrency market, daily mining income remains stable. Join the XRP mining revolution now: https://drmlminers.com/
Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions. Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@ and postsalemanualrequests@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi WaarichSenior Director, Investor
Yahoo
43 minutes ago
- Yahoo
Another federal judge orders AmeriCorps to reinstate workers, restore funds
An AmeriCorps member works in Philadelphia in this 2014 file photo. (Photo courtesy AmeriCorps) A second federal district judge in Maryland has ordered the Trump administration to reinstate AmeriCorps workers who were laid off without notice in April and to restore $400 million in funding and grants to nonprofit organizations. The preliminary injunction handed down Monday by District Judge Matthew Maddox comes a month and two days after a similar ruling in a separate AmeriCorps case in Maryland by U.S. District Judge Deborah Boardman — whose ruling is quoted heavily by Maddox. Both judges blocked moves by the Trump administration and the Department of Government Efficiency (DOGE) to shut down AmeriCorps programs, including the National Civilian Community Corps (NCCC), Volunteers in Service to America (VISTA) and various state and private grant programs. Boardman ruled in favor of 24 states and the District of Columbia that sued to block the DOGE cuts. Maddox ruled in favor of a number of nonprofits from around the country, members of an AmeriCorps labor union and three AmeriCorps service members. Both cases were a response to DOGE moves in mid-April to immediately terminate all NCCC projects, along with 2,000 NCCC participants, and to put more than 600 AmeriCorps staffers — about 85% of the agency's staff — on administrative leave, to be laid off less than two weeks later. Workers were ordered to immediately stop working and were locked out of AmeriCorps offices, email and other systems. About $80,000 raised to support Maryland AmeriCorps programs gutted by Trump Maddox said the workers and nonprofits that sued the Corporation for National and Community Service, which runs AmeriCorps, were likely to win on their claims that the abrupt government cuts were made without authority, failed to follow appropriate procedures and were likely to cause irreparable harm to the plaintiffs. Maddox wrote that the government 'cancelled approximately $400 million in AmeriCorps grants and terminated funding to both direct grantees and subgrantees of State Service Commission…. These actions have led to significant disruptions in the delivery of services that were previously funded by AmeriCorps and provided by the Nonprofit Plaintiffs.' 'This disruption has included the termination or suspension of assistance with college applications, provision of teachers to Indigenous school districts, housing assistance for low-income families, childhood literacy programs, summer and afterschool learning programs, and neighborhood revitalization programs, among other services,' he wrote. Maddox ordered the return of roughly $400 million in funding to 14 nonprofits that had grants to do AmeriCorps work, the reinstatement of hundreds of AmeriCorps Employees Union Local 2027 members who were put on administrative leave on April 15 and subsequently laid off, and the return of three AmeriCorps members who lost their positions as a result of the cuts. Boardman had ordered much of the same in her June 5 order. Besides Maryland and Washington, D.C., other states that sued, and are subject to Boardman's preliminary injunction, are Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Kentucky, Maine, Massachusetts, Michigan, Minnesota, Nevada, New Jersey, New Mexico, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, Vermont, Washington, and Wisconsin. SUPPORT: YOU MAKE OUR WORK POSSIBLE Maddox's order affects three unnamed AmeriCorps members as well as about 400 members of AmeriCorps Employees Union, AFSCME Local 2027. It also applies to 14 nonprofits: Elev8 in Baltimore; Red Cloud Indian School in South Dakota; Bur Oak Land Trust in Iowa; Partners for Campus-Community Engagement in Pennsylvania; National College Attainment Network in Washington, D.C.; Michigan College Access Network; North Carolina Housing Coalition; Housing and Community Development Network of New Jersey; Handson Suburban Chicago; Democracy Maine; the Service Collaborative of WNY in New York; Rainbow Labs in California; the SEED Coalition in Minnesota; and the Aspire Afterschool Learning in Virginia. Maddox gave the government 24 hours to file a status report confirming that all parties had been notified of his order and that the government was complying with it. It is to file an updated status report every two weeks.
Yahoo
an hour ago
- Yahoo
Prediction: Bitcoin Will Become a Reserve Currency
Bitcoin isn't an asset held by most central banks. It still has a handful of the properties that are common to reserve currencies. Therefore, it's likely that it will eventually be regarded as a reserve asset. 10 stocks we like better than Bitcoin › Gold has long been an asset that central bankers prefer to hold on their balance sheets. Today, with global finance digitizing by the month, an asset born entirely on the internet is now auditioning for the same role. That asset is Bitcoin (CRYPTO: BTC), and the audition is getting very serious. In fact, I predict that sometime within the next 10 years, this coin will become a reserve asset that at least a few central banks around the world will aspire to hold for the long term. There are a few things that clearly point toward a scenario where Bitcoin sits beside gold and U.S. Treasuries as an important reserve asset. Let's see what makes this scenario likely, and why things look brighter than ever for the cryptocurrency's future. A reserve asset must be reliably scarce, and this coin has that quality covered better than any other such asset. Bitcoin's supply is hard-capped at 21 million coins, and 93.3% of that total is already in circulation, leaving very little future dilution possible. As with precious metals, substantial capital investment is required to mine the unexploited supply. But unlike in metals, with Bitcoin, there can be no fresh discovery that will boost output. That makes its supply even more reliably constrained than gold over the very long run. Furthermore, its issuance falls by 50% roughly every four years in the halving, meaning the asset's inflation rate trends toward zero on an automatic schedule. That sounds like something central bankers would appreciate, as it eliminates some of the need to rebalance the value of the holding due to any drift caused by inflation. Another big plus is that a growing slice of that finite pile is migrating into sovereign and quasi-sovereign hands. Such holders are not apt to dump their holdings abruptly and cause volatility. Governments collectively hold 2.3% of all mined coins. That's more than 463,000 Bitcoin, mostly sourced from seizures that authorities decided not to auction away. The floating supply shrinks further when corporations add coins to their treasuries or exchange-traded fund (ETF) sponsors warehouse inventory for retail buyers. Scarcity is only half the story here. Neutrality is the other. Bitcoin is not an asset with any regard for politics or sanctions lists in any specific country. For central banks managing currency volatility, that independence can be a hedge against counterparties weaponizing payment rails. Gold does the same job, but moving bullion across borders is slow and expensive. A coin with digital scarcity and which clears in minutes is an upgrade that many policymakers will not ignore forever. A reserve asset must be easy to hold in custody, and transparent to audit. That infrastructure is arriving fast for Bitcoin. Custody is easier than ever. The Securities and Exchange Commission's (SEC's) reversal of its 2022 guidance this February freed Wall Street banks to hold digital assets without capital charges, opening the door for giants to compete for official-sector mandates. Next come regulated wrappers. ETFs mean that central banks that are barred from trading on crypto exchanges can buy ETF shares as easily as they buy gold ETFs today. There are no more major barriers to access, whether by using a financial instrument or by buying the coin on-chain directly. This also ensures that the asset remains highly liquid across financial systems, another desirable trait for a reserve asset. The clearest signal that Bitcoin will be a reserve asset, however, comes from monetary authorities themselves. In January, the Czech National Bank disclosed that it is studying a multi-billion-dollar Bitcoin allocation for its reserves, the first such public exploration by a Western central bank. Other central banks, like the one in Switzerland, have already ruled out onboarding the coin as a reserve asset. But even a pilot stake by one midsize central bank could pressure peers to craft a policy response, lest they appear unprepared if Bitcoin rallies sharply. Of course, Bitcoin's price can still whipsaw, and a coordinated crackdown by major economies would chill adoption. But the direction of travel is clear: More liquidity is here, as is more sovereign interest. Assuming regulatory momentum stays positive and custody continues to institutionalize, Bitcoin's jump from outsider money to a reserve asset looks less like science fiction and more like the natural progression of digital finance. For investors, the implication is straightforward. Reserve demand is sticky and insensitive to day-to-day volatility. Gold purchased by central banks usually remains in their reserves for decades. A similar mindset would apply to Bitcoin. That extra layer of permanent demand could tighten supply even more, driving the coin's value higher over long timeframes. Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Alex Carchidi has positions in Bitcoin. The Motley Fool has positions in and recommends Bitcoin. The Motley Fool has a disclosure policy. Prediction: Bitcoin Will Become a Reserve Currency was originally published by The Motley Fool
